Glenmark launches generic Olanzapine injection in US

New Delhi: Glenmark Pharmaceuticals on Monday announced the launch of the generic version of Olanzapine injection, indicated for treatment of schizophrenia and bipolar disorder, in the US.

The company's arm Glenmark Pharmaceuticals Inc, USA has launched Olanzapine for injection of strength 10 mg/vial, single-dose vial, Glenmark said in a regulatory filing.

Also Read: US, West Asia drag India's pharma exports growth


The company's Olanzapine for injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa intramuscular injection 10 mg/vial, of Cheplapharm Registration GmbH, it added.

"The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel," Glenmark President & Business Head, North America, Marc Kikuchi said.

Also Read: Sun Pharma secures relief in 'Pantocid' trademark dispute

Citing IQVIA sales data for the 12-month period ended May 2026, Glenmark said the Zyprexa intramuscular injection market achieved annual sales of approximately USD 25.4 million.